Genetic Divergence of Influenza A(H3N2) Amino Acid Substitutions Mark the Beginning of the 2016-2017 Winter Season in Israel

Aharon Glatman-Freedman
New York Medical College

Yaron Drori
Sharon Beni
Nehemya Friedman
Rakefet Pando

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs

Part of the Respiratory Tract Diseases Commons, and the Virology Commons

Recommended Citation
Glatman-Freedman, A., Drori, Y., Beni, S., Friedman, N., Pando, R., Sefty, H., Tal, I., McCauley, J., Rahav, G., Keller, N., Shohat, T., Mendelson, E., Hindiyeh, M., & Mandelboim, M. (2017). Genetic Divergence of Influenza A(H3N2) Amino Acid Substitutions Mark the Beginning of the 2016-2017 Winter Season in Israel. Journal of Clinical Virology, 93, 71-75. https://doi.org/10.1016/j.jcv.2017.05.020

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.
Authors
Aharona Glatman-Freedman, Yaron Drori, Sharon Beni, Nehemya Friedman, Rakefet Pando, Hanna Sefty, Ilana Tal, John McCauley, Galia Rahav, Nathan Keller, Tamy Shohat, Ella Mendelson, Musa Hindiyeh, and Michal Mandelboim

This article is available at Touro Scholar: https://touroscholar.touro.edu/nymc_fac_pubs/168
Short communication

Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016–2017 winter season in Israel

Aharona Glatman-Freedmanb,c, Yaron Drori, Sharon Alexandra Benie, Nehemya Friedmanb,d, Rakefet Pandoa,d, Hanna Seftya, Ilana Tal, John McCauley, Galia Rahave, Nathan Keller, Tamy Shohata, Ella Mendelson, Musa Hindiyeh, Michal Mandelboim, Nathan Keller, and Galia Rahave

a The Israel Center for Disease Control, Israel Ministry of Health, Tel-Hashomer, Ramat Gan, Israel
b Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
cb Department of Pediatrics and Family and Community Medicine, New York Medical College, Valhalla, New York, USA
d Department of Pediatrics and Family and Community Medicine, New York Medical College, Valhalla, New York, USA
e Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
f Division of Infectious Diseases, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
WHO Collaborating Centre for Reference and Research on Influenza, Crick Worldwide Influenza Centre, the Francis Crick Institute, London, United Kingdom
h Microbiology Laboratory, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
i Ariel University, Ariel, Israel

ARTICLE INFO

Keywords:
Influenza A
H3N2
Influenza vaccine
Clade 3C.2a1

ABSTRACT

Background: Influenza vaccine composition is reevaluated each year due to the frequency and accumulation of genetic changes that influenza viruses undergo. The beginning of the 2016–2017 influenza surveillance period in Israel has been marked by the dominance of influenza A(H3N2).

Objectives: To evaluate the type, subtype, genetic evolution and amino acid substitutions of influenza A(H3N2) viruses detected among community patients with influenza-like illness (ILI) and hospitalized patients with respiratory illness in the first weeks of the 2016–2017 influenza season.

Study design: Respiratory samples from community patients with influenza-like illness and from hospitalized patients underwent identification, subtyping and molecular characterization. Hemagglutinin sequences were compared to the vaccine strain, phylogenetic tree was created, and amino acid substitutions were determined.

Results: Influenza A(H3N2) predominated during the early stages of the 2016–2017 influenza season. Noticeably, approximately 20% of community patients and 36% of hospitalized patients, positive for influenza(a), received the 2016–2017 influenza vaccine. The influenza A(H3N2) viruses demonstrated genetic divergence from the vaccine strain into three separate subgroups within the 3C.2a clade. One resembled the new 3C.2a1 subclade, one resembled the recently proposed 3C.2a2 subclade and the other was not previously described.

Diversity was observed within each subgroup, in terms of additional amino acid substitutions.

Conclusions: Characterization of the 2016–2017 A(H3N2) influenza viruses is imperative for determining the future influenza vaccine composition.

1. Background

Influenza vaccination composition is evaluated each year due to the frequency and accumulation of genetic changes that influenza viruses undergo. The beginning of the 2016–2017 influenza surveillance period in Israel has been marked by the dominance of influenza A(H3N2) virus infection both among community and hospitalized patients. Influenza A(H3N2) is considered the most common cause of seasonal influenza [1], and has been associated with most influenza-related deaths [2].

Hemagglutinin (HA) amino acid (AA) substitutions are considered to occur more frequently for influenza A(H3N2) than influenza A(H1N1) viruses [3], and vaccine effectiveness (VE) against influenza A(H3N2) has been overall lower than VE against influenza A(H1N1) or against influenza B [4]. Thus, it is of paramount importance to detect AA substitutions in the circulating influenza A(H3N2) viruses relative to the recommended vaccine strain as early in the influenza season as possible. In this work, we analyzed influenza A(H3N2) viruses detected early in the season in respiratory samples of influenza patients that...
were either vaccinated or not vaccinated with the 2016–2017 influenza vaccine.

### 2. Study design

#### 2.1. Sample collection

Respiratory samples were collected from patients hospitalized with respiratory illness at the Chaim Sheba Medical Center, Israel, and from patients with influenza-like illness (ILI) from 26 outpatient sentinel clinics throughout Israel. The latter were collected as a part of the Israel Center for Disease Control (ICDC) surveillance program for respiratory viruses morbidity. Sheba Medical Center institutional review board (IRB) approval was obtained (Helsinki Number 1967-15-SMC).

#### 2.2. Laboratory techniques

Viral genomic RNA was extracted from respiratory samples using the NucliSENS easyMAG (BioMerieux, France). Influenza A, Influenza B and A(H1N1)pdm09 infection was detected by using a panel of real-time reverse transcription-PCR (rRT-PCR), as previously described [5,6]. For influenza A(H3N2) detection and sequencing specific primers were used as previously described [7]. RT-PCR products were sequenced using ABI PRISM Dye Deoxy Terminator cycle sequencing kit (Life Technology, Foster City, CA, USA). Reaction mixtures were analyzed on Applied Biosystems 3500 sequencer analyzer.

Nucleic acid sequences were aligned and compared using the Sequencer® 5.0 program (Gencodes Corporation, Ann Arbor, MI). To infer the evolutionary relationships and the most recent common ancestor (MRCA) for the influenza A(H3N2) virus HA sequences, a Bayesian Markov chain Monte Carlo (MCMC) method was applied using a relaxed molecular clock, as implemented in the BEAST program [8].

### Table 1

Influenza A(H3N2) virus hemagglutinin sequences used in phylogenetic analysis.

| Virus isolate | Sequence source | Accession Number | Country | Originating laboratory |
|---------------|-----------------|------------------|---------|------------------------|
| A/Texas/50/2012 | GISAID EpiFlu | EP1377499 | United States | Texas Department of State Health Services-Laboratory, Austin, United States |
| A/Nevada/34/2015 | GISAID EpiFlu | EP1633977 | United States | Southern Nevada Public Health Lab United States |
| A/Bolzano/7/2016 | GISAID EpiFlu | EP1773595 | Italy | Istituto Superiore di Sanità Roma, Italy |
| A/Hawaii/54/2016 | GISAID EpiFlu | EP1814213 | United States | State of Hawaii Department of Health Medical Microbiology Branch, United States |
| A/Wisconsin/85/2016 | GISAID EpiFlu | EP1857055 | United States | Wisconsin State Laboratory of Hygiene, Virology Unit, United States |
| A/Illinois/7/2016 | GISAID EpiFlu | EP1752842 | United States | Illinois Department of Public Health-Chicago, United States |
| A/Hong Kong/4801/2014 | GISAID EpiFlu | EP1539574 | China | Government Virus Unit, Hong Kong (SAR) |
| A/Nebraska/04/2014 | GISAID EpiFlu | EP1520356 | United States | Nebraska Public Health Lab, United States |
| A/Switzerland/971529/2013 | GISAID EpiFlu | EP1530667 | Switzerland | Hospital Cantonal Universitaire de Geneves, Switzerland |
| A/Somara/73/2013 | GISAID EpiFlu | EP1460558 | Russian Federation | WHO National Influenza Centre, Russian Federation |
| A/New Castele/22/2014 | GISAID EpiFlu | EP1543132 | Australia | WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia |
| A/Victoria/361/2011 | GISAID EpiFlu | EP1349103 | Australia | A Melbourne Pathology, Victoria Pde, Australia |
| A/Perth/16/2009 | GISAID EpiFlu | EP1210071 | Australia | WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia |
| A/Wyoming/3/2003 | GISAID EpiFlu | EP1385944 | United States | Not available |
| A/Israel/P451/2015 | GISAID EpiFlu | EP1620485 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/P291/2014 | GISAID EpiFlu | EP1563104 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/P659/2015 | GISAID EpiFlu | EP1620486 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/P151/2014 | GISAID EpiFlu | EP1620489 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/P687/2015 | GISAID EpiFlu | EP1620488 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/17/2013 | GISAID EpiFlu | EP1426073 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/2125/2014 | GISAID EpiFlu | EP1539814 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/32/2013 | GISAID EpiFlu | EP1505186 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/Z774/2014 | GISAID EpiFlu | EP1514911 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/19/2013 | GISAID EpiFlu | EP1426075 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/2125/2013 | GISAID EpiFlu | EP1515191 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/35/2011 | GISAID EpiFlu | EP1354187 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/18/2011 | GISAID EpiFlu | EP1319254 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/20/2013 | GISAID EpiFlu | EP1426077 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/4/2011 | GISAID EpiFlu | EP1319256 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R83/2016 | GenBank | KY435815 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R147/2016 | GenBank | KY435816 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R199/2016 | GenBank | KY435817 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R245/2016 | GenBank | KY435818 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R246/2016 | GenBank | KY435819 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R248/2016 | GenBank | KY435820 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R250/2016 | GenBank | KY435821 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R255/2016 | GenBank | KY435822 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R256/2016 | GenBank | KY435823 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R274/2016 | GenBank | KY435824 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/R5990/2016 | GenBank | KY435825 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/B6014/2016 | GenBank | KY435826 | Israel | Central Virology Laboratory (NIC) Israel |
| A/Israel/B6105/2016 | GenBank | KY435827 | Israel | Central Virology Laboratory (NIC) Israel |

RT-PCR products were sequenced using ABI PRISM Dye Deoxy Terminator cycle sequencing kit (Life Technology, Foster City, CA, USA). Reaction mixtures were analyzed on Applied Biosystems 3500 sequencer analyzer.

Nucleic acid sequences were aligned and compared using the Sequencer® 5.0 program (Gencodes Corporation, Ann Arbor, MI). To infer the evolutionary relationships and the most recent common ancestor (MRCA) for the influenza A(H3N2) virus HA sequences, a Bayesian Markov chain Monte Carlo (MCMC) method was applied using a relaxed molecular clock, as implemented in the BEAST program (version 1.7.5). Trees were visualized and edited with the FigTree program (version 1.4.2) [8]. Selected HA sequences were deposited in GenBank under the following accession number designation: KY435815.1, KY435816.1, KY435817.1, KY435818.1, KY435819.1, KY435820.1, KY435821.1, KY435822.1, KY435823.1, KY435824.1, KY435825.1, KY435826.1 (Table 1).

#### 2.3. Cell culture and hemagglutination inhibition analysis

Influenza viruses were grown in Madin-Darby canine kidney (MDCK) cells stable transfected with the cDNA of human 2,6-sial-transferase (SIAT1) as previously described [9]. Hemagglutination assays were performed using fifty microliters of 0.75% guinea pig red blood cells in the presence of 20 nM oseltamivir.
The 388 samples obtained from community sentinel patients with ILI from October 2nd through December 9th, 2016, 59 (15.2%) were positive for influenza viruses. Of these, 56 (94.9%) were positive for influenza A(H3N2), one (1.7%) for influenza A(H1N1)pdm09 and two (3.4%) for influenza B virus. A total of 11 (20%) individuals who were infected with influenza A(H3N2) received the influenza vaccine 14 days or more prior to developing ILI.

Out of the 1023 samples received from hospitalized patients, 55 (5.4%) were positive for influenza; of these, 53 (96.4%) were positive for influenza A(H3N2), one (1.8%) for influenza A(H1N1)pdm09, and one (1.8%) for influenza B. Nineteen (36%) of the influenza A(H3N2)-hospitalized patients received the influenza vaccine 21 days or more prior to hospitalization, 13 were not vaccinated and for 21 patients vaccine information was unavailable. All hospitalized patients had underlying chronic diseases: 34% had cardiovascular diseases, 28% pulmonary diseases, 19% malignancy, 15% hypertension, 6% diabetes, 4% neurologic diseases, 4% endocrine/metabolic diseases and 4% were pregnant.

Sequence analysis of the HA gene of 18 influenza A(H3N2) viruses (13 from outpatient sentinel clinic samples, and five hospital samples) that were representative of the entire study period was carried out.

Table 2. Amino acid (AA) substitutions in the HA gene for influenza A(H3N2) viruses from Israel. Colored cells highlight AA substitutions that are common to all viruses that are part of a certain AA substitution group. Dots represent AAs that match the vaccine A(H3N2) virus sequence. Sample numbers are highlighted in color according to influenza vaccination status: vaccinated—yellow, non-vaccinated—pink, unknown—brown. AA glycosylation is marked in bold letters. (For interpretation of the references to color in this table legend, the reader is referred to the web version of this article.)

| HA Subunits | Clade | HA1 | HA2 |
|-------------|-------|-----|-----|
| Codon position HA | 27 | 31 | 33 | 78 | 92 | 93 | 106 | 121 | 122 | 131 | 142 | 144 | 168 | 171 | 173 | 214 | 219 | 245 | 246 | 261 | 262 | 311 | 77 | 150 | 155 | 176 |
| Antigenic site | A | A | A | A | D | D | D | B | C |
| A/Hong Kong/4801/2014 | 3C.2a | K | N | R | G | K | A | A | N | T | R | S | M | N | Q | I | S | I | N | R | S | H | J | G | G | V |
| All/Israel/R38/2016 | 3C.2a | K | G | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R39/2016 | 3C.2a | K | G | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R41/2016 | 3C.2a | V | G | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R5990/2016 | 3C.2a | B | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R240/2016 | 3C.2a | D | K | K | H | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R255/2016 | 3C.2a | D | K | K | H | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R59/2016 | 3C.2a | D | K | K | H | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R60/2016 | 3C.2a | D | K | K | H | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R256/2016 | 3C.2a | Q | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R256/2016 | 3C.2a | Q | T | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R246/2016 | 3C.2a | R | Q | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R256/2016 | 3C.2a | Q | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R127/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R199/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R245/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/R274/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B53/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B60/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B61/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B62/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B63/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B64/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |
| All/Israel/B65/2016 | 3C.2a | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K | K |

Table 2 demonstrates three main different groups of AA substitutions as compared with the vaccine A/Hong Kong/4801/2014 (H3N2) cell-propagated virus. Group 1 had the AA substitutions N171K (HA1), I77V (HA2) and G155E (HA2) which define the newly described clade 3C.2a1 [11]. Group 2 had the T313K (HA1) and R261Q (HA1) substitutions, with an additional substitution in codon position 142 (HA1), consisting of either R142K or R142E. Group 3 had the N121K (HA1) and S144K (HA1) substitutions (Table 2).

Ninety four percent (18 of 19) of the viruses had AA substitutions in antigenic site A (Table 2). Specifically, N121K (HA1) occurred in 67% (12 of 18) of the viruses, S144K (HA1) was observed in 56% (10 of 18), and T313K (HA1) occurred in 22% (4 of 18) of the viruses. Thirty three percent (6 of 18) of the viruses had AA substitutions in position 142 (HA1); 3 (16.7%) were R142K, 2 (11%) R142G and 1 (5.5%) was R142E.

Two AA substitutions, N122D and N246Y, resulted in a loss of a potential glycosylation site (Table 2).
The other two influenza viruses that were analyzed by HAI were recognized by an antiserum raised against a cell culture-propagated cultivar of the currently recommended vaccine virus A/Hong Kong/4801/2014 at titers 4-fold lower and 8-fold lower than the titer of the antiserum for the homologous virus. An antiserum raised against the egg-propagated vaccine virus A/Hong Kong/4801/2014 also recognized the two viruses analyzed so far at titers 4-fold or greater lower than the titer of the antiserum for the homologous virus. These results are available in the report of the Vaccine Composition Meeting held in February [13].

Fig. 1. Models of structures of representative influenza A(H3N2) viruses that circulated in Israel in the beginning of the 2016–2017 season. Each structure represents one amino acid combination that circulated in Israel in the beginning of the 2016–2017 influenza season. The arrow labels are colored according to the different groups of aa substitutions, similar to the group colors in Table 2. The 3 groups are indicated.

Fig. 2. Phylogenetic analysis of hemagglutinin gene sequences of influenza A(H3N2) viruses that circulated in Israel in the beginning of the 2016–2017 season. Analysis was performed with respect to A(H3N2) influenza viruses that circulated in Israel in previous seasons and reference A(H3N2) influenza viruses. These virus sequences were obtained from Global Initiative on Sharing All Influenza Data (GISAID) (Table 1). Colored branches represent different groups of amino acid substitutions, matching the colors of AA substitution groups in Fig. 1. The 3 groups are indicated.
4. Discussion

Surveillance of influenza viruses at the beginning of the influenza season is of paramount importance for evaluation of current infecting viruses and preparation of the appropriate next season vaccine. Israel is located in the northern hemisphere in western Asia. Influenza A(H3N2) predominated in Israel during the preceding seasons of 2010/2011, 2011/2012, 2013/2014 and 2014/2015, in which it constituted 59.5%, 84.3%, 76.4% and 92.2% of the influenza-positive nasal-throat samples obtained from ILI sentinel patients, respectively [14–17]. During that period, the influenza A(H3N2) vaccine component was modified several times [18]. Amino acid substitutions in the HA protein are considered to occur more frequently in influenza A(H3N2) than in influenza A(H1N1) [3,19,20], and a significant drift was detected during the 2014–2015 season in the northern hemisphere, dominated by the 3C.2a clade [7,21]. Based on available vaccination data, 20% of ILI sentinel patients and at least 36% of hospitalized influenza A(H3N2)-positive cases became ill in the beginning of the 2016-2017 season despite being vaccinated.

In this regard, during the 2014–2015 influenza season that was dominated by a drifted influenza A(H3N2), approximately 20% of influenza A(H3N2)-positive influenza received the influenza vaccine [7].

Nucleotide sequencing revealed several differences as compared to the 2016-2017 influenza A(H3N2) vaccine strain. These changes demonstrated genetic divergence into three groups of AA substitution combinations. One of these combinations (Group 1) belonged to the newly described clade 3C.2a1 [11] and another (Group 3) was related to the recently proposed clade 3C.2a2. The remaining combination (Group 2) was most recently identified also in Europe [15].

It is interesting to note that influenza A(H3N2) was detected only in 1.7% of positive influenza samples received from outpatient sentinel patients with ILI during the 2015–2016 influenza season in Israel [22]. Thus, lack of a previous year exposure coupled with the mutations observed in the circulating viruses may contribute to the spread and dominance of influenza A(H3N2) during the present season.

Mutations that cause antigenic drift occur most frequently in the gene encoding the HA surface glycoprotein, which constitutes the target of neutralizing antibodies [23]. Influenza A(H3N2) has five neutralizing antigenic sites designated by the letters A to E, with 131 amino acid positions within them associated with antigenic changes [23]. However, seven of these positions (145, 155, 156, 158, 159, 189 and 193), found in antigenic sites A and B, have been more likely to be associated with antigenic changes [23,24]. None of the AA substitutions detected in our study occurred in these seven positions. However, the HAI results may provide some evidence for a possible antigenic drift. It is interesting to note that recent mid-season influenza A(H3N2) vaccine effectiveness studies estimates ranged mostly between 38% and 43% [25–29], which are consistent with modest protection overall.

The detection of three clear and different groups of AA substitution suggestions, that continued characterization of influenza A(H3N2) is necessary to see which group will prevail, prior to the decision regarding the future influenza vaccine composition.

In summary, characterization of early-season influenza viruses is important prior to the decision regarding future influenza vaccine composition. Due to the more rapid molecular changes that occur in influenza A(H3N2), detecting these changes is of paramount importance.

Acknowledgements

The work at the WHO Collaborating Centre was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001030), the UK Medical Research Council (FC001030) and the Wellcome Trust (FC001030).

References

[1] K. Kim, Y. Kim, Population genetic processes affecting the mode of selective sweeps and effective population size in influenza virus H3N2, BMC Evol. Biol. 16 (2016) 156.
[2] H.K. Lee, J.W. Tang, T.P. Leh, L.L. Ons, E.S. Koay, Predicting clinical severity based on substitutions near epitope A of influenza A/H3N2, Infect. Genet. Evol. 34 (2015) 292–297.
[3] N. Tewawon, S. Prachayangprecha, P. Wichitawattana, S. Korkong, S. Klungsung, et al., Assessing antigenic drift of seasonal Influenza A(H3N2) and A(H1N1)pdm09 viruses, PLoS One 10 (10) (2015) e0139958.
[4] E.A. Belongia, M.D. Simpson, J.P. King, M.E. Sundaram, N.S. Kelley, M.T. Osterholm, et al., Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies, Lancet Infect. Dis. 16 (8) (2016) 842–951.
[5] T. Meninger, M. Hendiyeh, L. Regev, H. Sherbany, E. Mendelson, M. Mandelboim, Relationships between A(H1N1)pdm09 influenza infection and infections with other respiratory viruses, Influenza Respir. Viruses 8 (4) (2014) 422–430.
[6] M. Hendiyeh, V. Levy, R. Azar, N. Varsano, L. Regev, Y. Shalev, et al., Evaluation of a multiplex real-time reverse transcriptase PCR assay for detection and differentiation of influenza viruses A and B during the 2001–2002 influenza season in Israel, J. Clin. Virol. 43 (2) (2010) 192–199.
[7] M. Mandelboim, A. Glatman-Freedman, Y. Drori, H. Sherbany, R. Pando, H. Setfy, et al., Ineffectiveness of the 2014–2015 H3N2 influenza vaccine, Oncotarget 7 (2) (2016) 192.
[8] A.J. Drummond, M.A. Suchard, D. Xie, A. Rambaut, Bayesian phylogenetics with BEAUti and the BEAST 1.7, Mol. Biol. Evol. 29 (8) (2012) 1969–1973.
[9] M. Matrosovich, T. Matrosovich, J. Carr, N.A. Roberts, H.D. Klenk, Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors, J. Virol. 77 (15) (2003) 8418–8425.
[10] WHO Global Influenza Surveillance Network, Manual for the laboratory diagnosis and virological surveillance of influenza viruses, 2018, (2011) http://apps.who.int/gisrkt/sistrom/10665/44518/1/9789241548090_eng.pdf.
[11] World Health Organization, Recommended composition of influenza virus vaccines for use in 2017 southern hemisphere influenza season, 2016, (2017) http://apps.who.int/iris/bitstream/10665/260888/1/WHO-VAC-RHR-17.2-eng.pdf.
[12] H. Harvala, D. P ramp ton, P. Grant, J. Raffle, R.B. Ferns, Z. Kozlakidis, et al., Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017, Euro Surveill. 22 (8) (2017) 297.
[13] Worldwide Influenza Centre, The Francis Crick Institute. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2017–2018, (2017) www.crick.ac.uk/media/358671/crick_nh_vcm_report_feb_2017_v2.pdf.
[14] Israel Center for Disease Control Surveillance of influenza-like illness in Israel, Weekly update report for Week 16, ending 18-April-2015. 2015. www.who.int/ flu/vaccines/virus/recommendations/201609_recommendation.pdf.
[15] Israel Center for Disease Control Surveillance of influenza-like illness in Israel, weekly update report for week 19, ending 10-05-2014. http://www.health.gov.il/PublicationsFiles/u2014052814.pdf.
[16] Israel Center for Disease Control Surveillance of influenza-like illness in Israel, weekly update report for week 14, ending 09-04-2011. http://www.health.gov.il/PublicationsFiles/u14042011.pdf.
[17] Israel Center for Disease Control Surveillance of influenza-like illness in Israel, Weekly update report for week 16, ending 21-04-2012. http://www.health.gov.il/PublicationsFiles/u210412.pdf.
[18] Israel Center for Disease Control Surveillance of influenza-like illness in Israel, Weekly update report for week 15, ending 16-April-2016, 2016. www.who.gov.il/PublicationsFiles/u16042016e.pdf.
[19] B.F. Koel, D.F. Burke, T.M. Bestebroer, S. van der Vliet, G.C. Zongad, G. Vervaet, et al., Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution, Science (New York, NY) 342 (6161) (2013) 976–979.
[20] L. Popova, K. Smith, A.H. West, P.C. Wilson, J.A. Dickinson, L.F. Thompson, et al., Interim estimates of 2016–17 seasonal influenza vaccine effectiveness – United States, February 2017, MMWR Morb. Mortal. Wkly. Rep. 66 (6) (2017) 167–171.
[21] E. Kissling, M. Roudy, Early 2016–17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe, Euro Surveill. 22 (7) (2017).
[22] J.M. Skowronski, C. Chambers, S. Sabaduc, J.A. Dickinson, A.L. Wint, G. De Serres, et al., Interim estimates of 2016–17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017, Euro Surveill. 22 (6) (2017).
[23] M.P. Hergarten, U. Baum, M. Brying, N. Ikonen, A. Haveri, A. Wiman, et al., Mid-season real-time estimates of seasonal influenza vaccine effectiveness in persons 65 years and older in register-based surveillance, Stockholm County, Sweden, and Finland, January 2017, Euro Surveill. 22 (6) (2017).
[24] J. Castilla, A. Navascues, I. Casado, J. Diaz-Gonzalez, A. Perez-Garcia, L. Fernando, et al., Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis, Euro Surveill. 22 (7) (2017).